As shown in Supplementary Table S3, PHF5A overexpression was significantly associated with primary tumour sites (P = 0.0171), T classifications (P = 0.0115), and clinical stages (P = 0.0374) in the HNSCC validation cohort. Here, PHF5A is linked to neoplasm.